Pay Your Bill Online Test Menu Test Results Online LabCare Plus Results

CV Advance Cardiac Assessment Panel

Download Brochure

Shiel Medical Laboratory’s CV Advance Cardiac Assessment Panel contains key biomarkers recognized as clinically relevant in identifying cardiovascular disease and CVD risk. With Shiel’s exclusive Oxidized LDL Triple Market Test as the CV Advance Panel’s core component, this panel of blood tests offers a comprehensive assessment of a patient’s cardiac health.

In addition to our Oxidized LDL Triple Marker Test, the CV Advance Cardiac Assessment Panel includes the following:

Lp(a)

The Lp(a) is a genetically inherited biomarker and elevated Lp(a) can be found in patients with normal Lipid Panel results. Excess Lp(a) is the most common disorder in patients with premature coronary artery disease and elevated levels are associated with an increased risk for development of coronary artery disease and cerebral vascular disease. Lp(a) remains relatively constant over an individual’s lifetime and is not easily modified by lifestyle changes or drugs. When Lp(a) is high it may suggest the need for more aggressive treatment of other, more treatable risk factors and goals should be to lower elevated LDL Cholesterol and/or increase HDL Cholesterol. Conditions which may contribute to an elevated level of Lp(a) include estrogen depletion, severe hypothyroidism, uncontrolled diabetes, chronic renal failure, and nephrotic syndrome. There are no known problems associated with low Lp(a).

Lp-PLA2

Lp-PLA2 is a significant predictor of patients at risk for CV events and ischemic stroke and a complement to the other tests in the CV Advance Panel. Patients with elevated Lp-PLA2 levels are at a 2-fold increase in risk for CV events and both first and recurrent strokes. Lp-PLA2 predicts risk independent of, and complementary to, hs-CRP when evaluating a person’s level of underlying inflammation, independent of systemic inflammation, and when both Lp-PLA2 and CRP results are elevated, risk for CHD events and stroke increase 4-fold and 11-fold. Lp-PLA2 levels have been identified in early atherosclerosis and are associated with endothelial dysfunction. 

NMR LipoProfile

NMR LipoProfile test provides a patient’s LDL particle (LDL-P) number. The higher the number of LDL particles, the greater the likelihood for them to enter the arterial wall and to form atherosclerotic plaque. LDL-P, along with LDL-C, offers a more complete picture of CVD risk for personalized LDL management. For individuals with discordant LDL-C and LDL-P levels, the LDL-attributable atherosclerotic risk is better indicated by LDL-P.

CV Advance - Shiel Test # 5086
Specimen Requirements: One Spun SST, One Spun LipoNMR Tube (Black Top with Yellow Ring).